News

1 Underrated Reason to Buy This Market-Beating Stock
Eli Lilly (NYSE: LLY) has been one of the top-performing healthcare megacap stocks of the past decade. Eli Lilly is ...
Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way
Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...
4 Monster Stocks to Buy and Hold for the Next Decade
The U.S. equity market has been anything but calm in 2025, as several factors, including persistent trade tensions, rising ...
Investing Snacks5d
UBS Cheers Vertex’s Pain Cuts, Keeps $582 Target
UBS analyst Eliana Merle reaffirmed a Buy rating and a $582 price target for Vertex Pharmaceuticals, praising the adoption of ...
Investing Snacks6d
Vertex Flexes Muscle in Painkiller Game
Vertex Pharmaceuticals is riding high on analyst confidence, thanks to its leadership in NAV1.8 inhibitors and smart partnerships. Jefferies analyst Michael Yee recently reaffirmed a Buy rating, ...